Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Fast Is The Biologics CDMO Market Expected to Grow Between 2025 And 2029?
The market size for biologics CDMO has seen a rapid surge in growth in the past years. It is projected to expand from a value of $21.3 billion in 2024 to a figure of $24.15 billion in 2025, at a compound annual growth rate (CAGR) of 13.4%. The growth witnessed in the past can be credited to factors like an increase in the development of biologics, cost-effectiveness and flexibility, focus on core competencies, regulatory compliance and quality assurance, as well as the globalization of pharmaceutical supply chains.
The biologics CDMO market is projected to experience accelerated growth over the coming years, with the size potentially reaching a staggering $41.53 billion by 2029, reflecting a compound annual growth rate (CAGR) of 14.5%. This growth expected in the forecast period can be linked to factors like the burgeoning demand for biologic therapies, the rise of biosimilars and biobetters, infusion of capital in biomanufacturing infrastructure, the shift towards outsourcing intricate processes, emphasis on building resilient supply chains and risk management, harmonization of regulatory mandates, and faster approval procedures. The forecast period is likely to be characterized by key trends such as the expansion in capabilities to provide comprehensive solutions, the appropriation of single-use technologies, integrating continuous manufacturing processes, and the surfacing of specialized CDMOs.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14056&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Biologics CDMO Market?
The escalating need for cell and gene therapy is set to turbocharge the expansion of the biologic CDMO market. These novel medical methods use live cells or genetic components to tackle the root causes of diseases at the cellular or genetic tier, offering potential remedies for disorders that are hard to control or incurable with conventional drugs. The appeal for cell and gene therapy is on the upswing due to their ability to present groundbreaking treatments for diseases by tackling the fundamental genetic or cellular triggers. Biologic CDMOs have proficiency in managing live cells, viral vectors, and genetic elements, promoting safe and effective production of cell and gene therapies. They also support biopharmaceutical firms to traverse regulatory stipulations and technical obstacles, thus easing the transition from research to clinical use. For example, The American Society of Gene & Cell Therapy (ASGCT), a leading professional organization in the US, reported that as of January 2023, the gene, cell, and RNA therapy pipeline witnessed a 7% increase in 2022, totalling 3,726 therapies under development. Among these, gene therapies account for 55%, non-genetically modified cell therapies contribute 22%, and RNA therapies make up 23%. Thus, the soaring demand for cell and genetic therapy is fuelling the expansion of the biologic CDMO market.
Which Key Market Segments Comprise the Biologics CDMO Market and Drive Its Revenue Growth?
The biologics cdmo market covered in this report is segmented –
1) By Cell Type: Mammalian, Non-Mammalian
2) By Product Type: Biologics, Biosimilars
Subsegments:
1) By Mammalian: Chinese Hamster Ovary (CHO) Cells, Human Embryonic Kidney (HEK) Cells, Other Mammalian Cells
2) By Non-Mammalian: Yeast Cells, Bacterial Cells, Insect Cells, Other Non-Mammalian Cells
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=14056&type=smp
Which Areas Are Leading Regions in the Biologics CDMO Market Expansion Across the Globe?
North America was the largest region in the biologics CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biologics CDMO market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theBiologics CDMO Market Direction?
Leading firms in the biologics CDMO market are designing cutting-edge solutions, including new cell lines, to improve efficiency and capabilities in biopharmaceutical development and manufacturing. These advances enable the production of therapeutic antibodies with superior effectiveness, addressing R&D obstacles in immunotherapy. For instance, in November 2023, Lonza Group, a Swiss manufacturer specializing in pharmaceuticals and biotechnology, unveiled GS Effex cell lines. These cell lines are designed to generate antibodies completely devoid of the sugar molecule fucose, thereby demonstrating enhanced potency without trading off other performance characteristics. This innovation solves immunotherapy R&D hurdles associated with the necessity for increased potency in antibody therapeutics. It is a robust, expandable, and efficient cell line that offers a lasting solution for therapeutic development, spanning from initial discovery research to commercial production.
View the full report here:
https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report
How Is the Biologics CDMO Market Conceptually Defined?
A biologics contract development and manufacturing organization (CDMO) is a service provider that supports pharmaceutical companies in the development and production of biologic drugs, which include vaccines, blood and blood components, allergens, somatic cells, gene therapies, tissues, and recombinant therapeutic proteins.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=14056
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model